Galectin Therapeutics eliminates $105.8 million debt in chairman note-to-equity conversion

PUBT · 1d ago
Galectin Therapeutics eliminates $105.8 million debt in chairman note-to-equity conversion
  • Galectin Therapeutics converted USD 105.8 million of debt into equity, eliminating USD 91 million of principal, effective July 31, 2026.
  • Chairman Richard E. Uihlein received 34,376,167 common shares at a blended average conversion price of about USD 3.07.
  • Shares outstanding rose to 100,849,644 as of July 31, 2026, strengthening the balance sheet.
  • A separate USD 10 million supplemental line of credit remains undrawn and available.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040800PRIMZONEFULLFEED9802691) on August 04, 2026, and is solely responsible for the information contained therein.